Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab + Dupilumab in Severe IgE-Mediated Food Allergy
NCT06369467Phase 1Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linvoseltamab in food allergy, sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at week 176, Adverse Events of Special Interest at week 176 and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
linvoseltamab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT06369467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369467.